Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Oversight and Government Reform, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Increases domestic medical supply production to reduce dependence on foreign sources.
The problem
The U.S. relies heavily on other countries for medicines and medical supplies. Supply chain problems during emergencies have shown this creates health and safety risks.
The proposal
The bill likely aims to boost American manufacturing of pharmaceuticals and medical devices through incentives, grants, or regulatory changes to strengthen domestic production capacity.
The impact
Pharmaceutical companies, manufacturers, and patients could see changes in drug availability, prices, and production locations. Healthcare workers and hospitals may experience supply chain improvements.
More domestic production means the U.S. has backup supplies during crises like pandemics. Americans won't depend solely on other countries when emergencies happen.
Building factories and hiring workers to make medicines and medical supplies creates jobs in the U.S. This supports local economies and manufacturing communities.
Reducing dependence on foreign suppliers protects America from supply disruptions caused by international conflicts or trade tensions.
Domestic production could speed up delivery times for medications and medical devices to American patients and hospitals.
Building new factories and equipment is expensive. Taxpayers may fund this through government money, and medicines might cost more.
Requiring domestic production could make it harder for newer, cheaper medicines to reach patients quickly compared to importing.
Other countries might respond negatively to U.S. protectionism, leading to disputes over trade and potentially higher costs for consumers.
American manufacturers may struggle to compete if other countries produce medicines more cheaply, potentially wasting resources.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.